Rare protein-disrupting variants in CETP and protection against vascular events
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Sequence variants that disrupt Cholesteryl Ester Transfer Protein (CETP) provide a genetic proxy for therapeutic inhibition, but their association with atherosclerotic vascular events has not been robustly established.
Objectives
To assess whether protein-disrupting CETP variants conferring lifelong reduced CETP activity lower atherosclerotic vascular event rates.
Methods
We tested associations between protein-disrupting CETP variants and atherosclerotic vascular and coronary artery disease across the All of Us Research Program and the UK Biobank using whole-genome sequences and linked health data. Predicted protein-disrupting variants were identified with LOFTEE and AlphaMissense. Gene-based burden testing used Firth’s logistic regression via REGENIE. Coronary artery disease was meta-analysed with FinnGen, Biobank Japan, and previous case-control studies. Restricted mean event-free survival to average life expectancy of 81 years was estimated in the UK Biobank.
Results
We included 1,515–4,575 carriers of CETP protein-disrupting variants and 848,000–1,585,000 non-carriers in combined populations with 126,000 atherosclerotic events and 246,000 coronary artery disease events, respectively. HDL cholesterol was 25% higher (0.35 mmol/L [14 mg/dL], P =4×10 -138 ) and non-HDL cholesterol was 6% lower (0.23 mmol/L [9 mg/dL], P =9×10 -8 ) in carriers. Atherosclerotic vascular event rates were lower in carriers (odds ratio, 0.73, 95% confidence interval, 0.62–0.87, P =3×10 -4 ). Coronary artery disease risk was also lower in carriers (odds ratio, 0.79, 95% confidence interval, 0.72–0.86, P =3×10 -7 ), reaching exome-wide significance. Carriers lived an average 1.0 years longer without atherosclerotic disease (95% confidence interval, 0.5-1.4, P =6×10 -5 ).
Conclusion
Protein-disrupting CETP variants were associated with reduced atherosclerotic vascular disease risk and longer disease-free survival.
